Company "to terminate all development efforts for MGI 136"; the compound (diethyldithiocarbamate) was in Phase III trials as a chemoprotective agent. Minneapolis-based MGI Pharma suspended the trials in February when an interim analysis of the data showed that patients on MGI-136 appeared to have a decreased tolerance for chemotherapy ("The Pink Sheet" Feb. 17, T&G-11)....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth